News | June 08, 2024
Sun Pharma to acquire stake in HaystackAnalytics
HaystackAnalytics is engaged in the business of developing genomic analysis software
HaystackAnalytics is engaged in the business of developing genomic analysis software
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
These abstracts report on the company's three lead drug candidates, including olverembatinib
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
